Summary
The future of Medicare’s drug price negotiations, initiated under Biden’s Inflation Reduction Act, is uncertain under the incoming Trump administration.
Medicare plans to announce 15 drugs for its next round of negotiations, potentially including Ozempic.
While Trump allies have signaled opposition to the program, ending it could be politically risky, as high medication costs affect many Americans.
Experts suggest Trump could leverage negotiations, particularly for Ozempic, to score political wins with his base, especially in rural areas, where weight-loss drugs and diabetes treatments are in demand.
You must log in or register to comment.
Doubt it.
Yes, but only because the company that owns the patent isn’t American, and it would be an immensely popular move.
